Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
Status: | Recruiting |
---|---|
Conditions: | Parkinsons Disease |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 30 - Any |
Updated: | 8/9/2017 |
Start Date: | June 2010 |
End Date: | December 2018 |
The Parkinson's Progression Markers Initiative (PPMI)
This is a observational, multi-center study to assess progression of clinical features,
imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy
controls (HC) and in PD patient subtypes.
The primary objective of this study is to identify clinical, imaging and biologic markers of
PD progression for use in clinical trials of disease-modifying therapies.
imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy
controls (HC) and in PD patient subtypes.
The primary objective of this study is to identify clinical, imaging and biologic markers of
PD progression for use in clinical trials of disease-modifying therapies.
PPMI will be a five-year natural history study (a minimum of 3-year involvement for each
subject) of de novo idiopathic PD patients and healthy controls. This study will also include
a SWEDD (subjects without evidence of dopaminergic deficit)and Prodromal populations.
All subjects will be comprehensively assessed at baseline and every three to six months
thereafter. Subjects will undergo clinical (motor, neuropsychiatric and cognitive) and
imaging assessments and will donate blood, urine, and cerebral spinal fluid (CSF). A blood
sample for DNA will be collected. Data will be collected by each site under uniformly
established protocols and data will be analyzed and stored at designated core facilities.
subject) of de novo idiopathic PD patients and healthy controls. This study will also include
a SWEDD (subjects without evidence of dopaminergic deficit)and Prodromal populations.
All subjects will be comprehensively assessed at baseline and every three to six months
thereafter. Subjects will undergo clinical (motor, neuropsychiatric and cognitive) and
imaging assessments and will donate blood, urine, and cerebral spinal fluid (CSF). A blood
sample for DNA will be collected. Data will be collected by each site under uniformly
established protocols and data will be analyzed and stored at designated core facilities.
Inclusion Criteria:
Parkinson Disease (PD) Subjects:
- A diagnosis of Parkinson disease for 2 years or less at Screening.
- Confirmation from imaging core that screening DAT scan is consistent with dopamine
transporter deficit, or if applicable a VMAT-2 PET scan consistent with vesicular
monoamine transporter deficit.
- Not expected to require PD medication with at least 6 months from Baseline.
- Male or female age 30 years or older at time of PD diagnosis.
Healthy Control (HC) Subjects:
• Male or female age 30 years or older at Screening.
Exclusion Criteria:
Parkinson Disease (PD) Subjects:
- Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or other PD
medication.
- Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days
of Baseline.
- Has taken levodopa or dopamine agonists prior to Baseline for more than a total of 60
days.
- Received any of the following drugs that might interfere with DAT imaging:
Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or
amphetamine derivative, within 6 months of Screening.
- Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
If applicable, currently taking medications that are known to cause QT-prolongation, or are
currently taking tetrabenazine (TBZ or amphetamine type medications.
- Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
coagulopathy or thrombocytopenia.
- Use of investigational drugs within 60 days prior to Baseline (dietary supplements
taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10).
Healthy Control (HC) Subjects:
- Current or active neurological disorder.
- First degree relative with idiopathic PD (parent, sibling, child).
- MoCA score < 26.
- Received any of the following drugs that might interfere with DAT imaging:
Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or
amphetamine derivative, within 6 months of Screening.
If applicable, currently taking medications that are known to cause QT-prolongation, or are
currently taking tetrabenazine (TBZ) or amphetamine type medications.
- Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
- Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
coagulopathy or thrombocytopenia.
- Use of other investigational drugs within 60 days prior to baseline (dietary
supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme
Q10).
SWEDD Subjects:
All PD criteria apply, as above, except a SWEDD subject must have confirmation from imaging
core that screening dopamine transporter SPECT scan shows no evidence of dopamine
transporter deficit or if applicable a VMAT-2 PET scan shows no evidence of vesicular
monoamine transporter deficit.
Prodromal Subjects:
Inclusion Criteria (Prodromal Subjects) 4.2.7.1. Subjects must have at least one of the
following characteristics:
Hyposmia:
1. Male or female age 60 years or older
2. Confirmation from olfactory core that olfaction as determined by UPSIT is at or below
the 10th percentile by age and gender
REM Behavior Disorder (RBD):
1. Male or female age 60 years or older
2. Confirmation from sleep core that subject's Polysomnography (PSG) meets criteria for
RBD
LRRK2:
1. Male or female age 60 years or older
2. Written confirmation or documentation from testing facility that the individual is
LRRK2 mutation positive 4.2.7.2. Confirmation from imaging core that screening
dopamine transporter SPECT scan is read as eligible (see below). About 80 subjects
will have a range of DAT deficit similar to subjects with early PD (mild to moderate
DAT deficit). About 20 subjects will be selected with no DAT deficit or minimal DAT
deficit similar in age, gender, and risk profile to those with mild to moderate DAT
deficit. 4.2.7.3. Ability to provide written informed consent in accordance with Good
Clinical Practice (GCP), International Conference on Harmonization (ICH), and local
regulations. 4.2.7.4. Willing and able to comply with scheduled visits, required study
procedures and laboratory tests. 4.2.7.5. Women may not be pregnant, lactating or
planning pregnancy during the course of the study. Includes a negative urine pregnancy
test on day of screening scan prior to injection (DaTSCAN).
Exclusion Criteria (Prodromal Subjects)
1. Current or active clinically significant neurological disorder or psychiatric disorder
(in the opinion of the Investigator).
2. GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator
discretion to enter study).
3. STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter
study.
4. A clinical diagnosis of dementia63 as determined by the investigator (Appendix 1).
5. A clinical diagnosis of Parkinson disease at the Screening visit as determined by the
Investigator.
6. Received any of the following drugs that might interfere with dopamine transporter
SPECT imaging: Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate,
reserpine, or amphetamine derivative, within 6 months of Screening.
7. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
8. Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
coagulopathy or thrombocytopenia.
9. Any other medical or psychiatric condition or lab abnormality, which in the opinion of
the investigator might preclude participation.
10. Use of investigational drugs or devices within 60 days prior to Baseline (dietary
supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme
Q10).
11. Previously obtained MRI scan with evidence of clinically significant neurological
disorder (in the opinion of the Investigator).
We found this trial at
19
sites
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Hubert H. Fernandez, MD
Phone: 216-444-1134
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
(404) 727-5640
Principal Investigator: Stewart A Factor, DO
Phone: 404-728-6427
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: David G. Standaert, MD PHD
Phone: 205-996-4033
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Joseph Jankovic, MD
Phone: 713-798-3951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Penelope Hogarth, MD
Phone: 503-494-1382
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Irene Richards, MD
Phone: 585-341-7515
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
Tampa, Florida 33620
(813) 974-2011
Principal Investigator: Robert Hauser, MD
Phone: 813-369-0764
University of South Florida The University of South Florida is a high-impact, global research university...
Click here to add this to my saved trials
Click here to add this to my saved trials
Boca Raton, Florida 33486
Principal Investigator: Stuart Isaacson, MD
Phone: 561-392-1818
Click here to add this to my saved trials
One Silber Way
Boston, Massachusetts 02215
Boston, Massachusetts 02215
(617) 353-2000
Principal Investigator: Samual Frank, MD
Phone: 617-638-7737
Boston University Boston University is no small operation . With over 33,000 undergraduate and graduate...
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Tanya Simuni, MD
Phone: 312-503-5645
Click here to add this to my saved trials
Cincinnati, Ohio 45229
Principal Investigator: Alberto Espay, MD, MSC
Phone: 513-558-6517
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
La Jolla, California 92093
(858) 534-2230
Principal Investigator: Douglas Galasko, MD
Phone: 858-622-5800
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
Click here to add this to my saved trials
New Haven, Connecticut 06510
Principal Investigator: David Russell, MD
Phone: 203-508-1524
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Matthew Stern, MD
Phone: 215-829-7374
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Jim Leverenz
Phone: 206-277-6977
Click here to add this to my saved trials
Sun City, Arizona 85351
Principal Investigator: Holly Shill, MD
Phone: 623-875-6521
Click here to add this to my saved trials
Sunnyvale, California 94089
Principal Investigator: Caroline M. Tanner, MD, PhD
Phone: 408-542-5664
Click here to add this to my saved trials
Click here to add this to my saved trials